Haleon
HLN
9.02
+0.15
+1.69%
Haleon
US · HLN
#553 by market cap
Listed 2022
9.02
+0.15
+1.69%
Live - 5344 symbols - heartbeat 76s ago
· 2026-10-08 08:39
Pre-market
9.09
+0.74%
After-hours
9.02
0.00%
Overnight
9.07
+0.55%
- Market cap
- 39.67B
- P/E (TTM)i
- 18.87
- P/Bi
- 1.83
- EPSi
- 0.49
- Div yieldi
- 2.11%
- 52W posi
- 17%
Reader sentiment
Are you bullish or bearish on HLN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.24, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year -1.81% YoY
Margins
- Gross margin
- 64.19%
- Operating margin
- 21.87%
- Net margin
- 15.11%
Key ratios & quality
- Enterprise valuei
- 46.91B
- PEG ratioi
- 1.16
- Altman Z-Scorei
- 3.24
PEG uses trailing P/E against the 3-year net income growth rate (16.29%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 8.48B | 9.89B | 9.55B | 10.86B | 11.30B | 11.23B | 11.03B |
| Gross profit | 4.80B | 5.91B | 5.95B | 6.58B | 6.75B | 6.82B | 7.08B |
| Selling & admin expenses | 3.60B | 4.22B | 4.09B | 4.48B | 4.41B | 4.45B | 4.36B |
| Research & development | 292.00M | 304.00M | 257.00M | 300.00M | 311.00M | 298.00M | 316.00M |
| Operating profit | 897.00M | 1.60B | 1.64B | 1.83B | 2.00B | 2.21B | 2.41B |
| Pretax profit | 886.00M | 1.59B | 1.64B | 1.62B | 1.63B | 1.91B | 2.15B |
| Tax | 199.00M | 410.00M | 197.00M | 499.00M | 517.00M | 435.00M | 472.00M |
| Net profit | 687.00M | 1.18B | 1.44B | 1.12B | 1.11B | 1.48B | 1.68B |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.14 | 0.25 | 0.30 | 0.23 | 0.23 | 0.31 | 0.37 |
| Line item | 2024-06 | 2024-09 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.78B | 2.78B | 2.76B | -- | -- | -- |
| Gross profit | 1.71B | 1.75B | 1.53B | -- | -- | -- |
| Selling & admin expenses | 1.15B | 1.09B | 1.11B | -- | -- | -- |
| Research & development | 73.00M | 76.00M | 78.00M | -- | -- | -- |
| Operating profit | 496.00M | 705.00M | 350.00M | -- | -- | -- |
| Pretax profit | 406.00M | 626.00M | 288.00M | -- | -- | -- |
| Tax | 93.00M | 127.00M | 66.00M | -- | -- | -- |
| Net profit | 313.00M | 499.00M | 222.00M | -- | -- | -- |
| Basic EPS | 0 | 0 | 0 | -- | -- | -- |
| Diluted EPS | 0.07 | 0.11 | 0.05 | -- | -- | -- |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 5.81B | 5.01B | 5.25B | 4.06B | 4.82B | 5.72B | 4.55B |
| Cash & ST investments | 340.00M | 334.00M | 347.00M | 606.00M | 994.00M | 2.20B | 1.26B |
| Inventory | 1.21B | 949.00M | 951.00M | 1.35B | 1.41B | 1.19B | 1.03B |
| Total assets | 35.71B | 34.13B | 34.45B | 34.82B | 34.06B | 34.32B | 32.63B |
| Total current liabilities | 4.27B | 4.01B | 4.24B | 4.37B | 4.64B | 5.81B | 4.93B |
| Short-term debt | 521.00M | 382.00M | 904.00M | 437.00M | 656.00M | 1.49B | 836.00M |
| Long-term debt | -- | -- | 0 | 9.89B | 8.69B | 8.54B | 7.66B |
| Total liabilities | 8,299,000,000.00 | 7,907,000,000.00 | 7,971,000,000.00 | 18,358,000,000.00 | 17,326,000,000.00 | 18,091,000,000.00 | 16,146,000,000.00 |
| Total equity | 27.41B | 26.22B | 26.48B | 16.46B | 16.73B | 16.22B | 16.48B |
| Retained earnings | 5.11B | 37.76B | 37.54B | 26.73B | 27.47B | 27.27B | 27.85B |
| Line item | 2024-06 | 2024-09 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 4.71B | -- | 5.72B | 4.14B | 4.55B | 4.29B |
| Cash & ST investments | 531.00M | -- | 2.20B | 676.00M | 1.26B | 826.00M |
| Inventory | 1.46B | -- | 1.19B | 1.13B | 1.03B | 1.07B |
| Total assets | 33.40B | -- | 34.32B | 31.83B | 32.63B | 32.58B |
| Total current liabilities | 5.62B | -- | 5.81B | 4.76B | 4.93B | 6.24B |
| Short-term debt | 1.45B | -- | 1.49B | 813.00M | 836.00M | 1.96B |
| Long-term debt | 7.33B | -- | 8.54B | 7.55B | 7.66B | 6.15B |
| Total liabilities | 16,689,000,000.00 | -- | 18,091,000,000.00 | 15,830,000,000.00 | 16,146,000,000.00 | 16,141,000,000.00 |
| Total equity | 16.71B | -- | 16.22B | 16.00B | 16.48B | 16.44B |
| Retained earnings | 27.53B | -- | 27.27B | 27.27B | 27.85B | 27.69B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 786.00M | 1.41B | 1.36B | 2.06B | 2.10B | 2.30B | 2.63B |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- | -- |
| Free cash flow | 543.00M | 1.09B | 1.06B | 1.74B | 1.76B | 1.98B | 2.22B |
| Dividends paid | -1.15B | -2.37B | -1.15B | -2.68B | -388.00M | -570.00M | -612.00M |
| Stock buybacks / issuance | -- | -- | -- | 0 | 0 | -619.00M | -654.00M |
| Ending cash balance | 329.00M | 323.00M | 406.00M | 611.00M | 994.00M | 2.21B | 1.30B |
| Line item | 2024-06 | 2024-09 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | -- | -- | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | 2.40 | 4.29 | 5.30 | 4.97 | 6.37 | 8.80 | 10.23 |
| ROA %i | 1.83 | 3.28 | 4.05 | 3.06 | 3.05 | 4.22 | 4.98 |
| ROIC %i | 2.35 | 4.20 | 5.14 | 4.46 | 4.98 | 6.48 | 7.39 |
| 5-year avg ROE %i | -- | -- | -- | -- | 4.66 | 5.94 | 7.13 |
| EBIT margin %i | 10.75 | 16.24 | 17.27 | 17.42 | 18.07 | 20.51 | 22.66 |
| FCF / sales %i | 6.40 | 11.01 | 11.08 | 15.98 | 15.61 | 17.65 | 20.14 |
| Current ratioi | 1.36 | 1.25 | 1.24 | 0.93 | 1.04 | 0.98 | 0.92 |
| Quick ratioi | 1.00 | 0.95 | 0.96 | 0.57 | 0.58 | 0.71 | 0.65 |
| Debt / assetsi | 1.80 | 1.43 | 2.88 | 29.99 | 27.69 | 29.44 | 26.31 |
| LT debt / equityi | 0.44 | 0.40 | 0.33 | 61.25 | 52.84 | 53.29 | 47.17 |
| Interest coveragei | 35.08 | 107.07 | 137.33 | 6.91 | 4.93 | 5.85 | 7.20 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 8.59 | 4.54 | 5.58 | 0.53 |
| Net income CAGR (3Y) %i | -- | -- | -- | 17.41 | -2.88 | 1.23 | 16.29 |
| FCF CAGR (3Y) %i | -- | -- | -- | 47.29 | 17.44 | 23.30 | 8.58 |
| Line item | 2024-06 | 2024-09 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 6.58 | -- | 8.80 | 9.35 | 10.23 | 10.04 |
| ROA %i | 3.22 | -- | 4.22 | 4.67 | 4.98 | 5.04 |
| ROIC %i | 5.18 | -- | 6.48 | 7.02 | 7.39 | 7.50 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 18.23 | 19.77 | 20.51 | 21.47 | 22.66 | 22.03 |
| FCF / sales %i | 16.78 | -- | 17.65 | 19.52 | 20.14 | 19.97 |
| Current ratioi | 0.84 | -- | 0.98 | 0.87 | 0.92 | 0.69 |
| Quick ratioi | 0.47 | -- | 0.71 | 0.59 | 0.65 | 0.50 |
| Debt / assetsi | 26.52 | -- | 29.44 | 26.56 | 26.31 | 25.25 |
| LT debt / equityi | 44.62 | -- | 53.29 | 47.93 | 47.17 | 38.25 |
| Interest coveragei | 5.29 | 5.19 | 5.85 | 6.28 | 7.20 | 7.58 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Oral health is the largest reported line at 31.38% of revenue, across 6 reported segments.
- No single line clears half of revenue; Pain relief is next at 23.25%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Oral health31.38%
Pain relief23.25%
Respiratory health16.98%
Vitamins, minerals and supplements15.28%
Digestive health8.95%
Therapeutic Skin Health and Other4.17%
Region
Rest of the World56.11%
United States and Puerto Rico31.44%
China9.06%
UK3.39%
Quote time 2026-10-08 08:39:59 · For reference only, not investment advice and not tailored to your situation.